Unsere Studien

A Randomised, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations

A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with
tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD.

BAL- Studie
"The development of nanoparticle protein corona from components of human bronchoalveloar lavage fluid: characterization and use in in vitro cell exposure systems highlighting the significance of nanoparticle exposures to those with inflammatory lung disorders, such as COPD, and pulmonary infections".

An exploratory, 12 week, randomised, partially double-blinded, placebo-controlled, parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed dose
combination or tiotropium (both delivered by the Respimat® inhaler), supervised exercise training and behaviour modification on exercise capacity and physical activity in patients with Chronic Obstructive
Pulmonary Disease (COPD)

German COPD and Systemic Consequences - Comorbidities Net work

FLAME - Studie
A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled
study to compare the effect of QVA149 (indacaterol maleate/ glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD

A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

Efficacy and safety of Aclidinium/Formoterol Fumarate Fixed-Dose Combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease

NETs in COPD- Studie
Untersuchung der Bedeutung von neutrophilen Netzen bei COPD

REACT- Studie
Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 μg versus placebo

SCOPE- Studie
Salzburg Chronic Obstructive Pulmonary disease- Exercise and Oxygen Study

SCOT Registry
Small Cell Lung Cancer registry to describe patient characteristics, treatment patterns and outcomes

TONADO- Studie
A randomized, double-blind, parallel group study to assess teh efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5μg / 5μg; 5μg/5μg) (delivered by Respimat® Inhaler) compared with teh individual components (2.5μg and 5μg tiotropium, 5μg olodaterol) (delivered by Respimat® Inhaler) in patients with chronic obstructive pulmonary disease‘


Randomized, double-blind, placebo-controlled, multicenter study comparing
ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis


A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib

A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and
Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients
receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung
Cancer (Stage IIIB – IV)

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

A randomized, multicenter, double-blind, Phase 3 Trial comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in subjects with newly diagnosed extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)

Nivolumab I Studie
An Open-label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Nivolumab II Studie
An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC)

Lung cancer Audit
The National Lung Cancer Audit Austria

LUX LUNG 8- Studie
A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum based chemotherapy

Marquee- Studie
A phase III, randomized, double-blinded, placebo-controlled study of ARQ197 plus Erlotinib versus placebo plus Erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC)

EGFR- Studie
A Multi-center, Randomized, Double-blind, Placebo controlled, Phase III Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors

Idiopatic Lung Fibrosis
Pirfinidone Beobachtungsstudie
Post-Authorisations Safety Study (PASS) of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting

Prifinidone- Studie
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone

Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH | Müllner Hauptstraße 48 | A-5020 Salzburg
Telefon: +43 (0)5 7255-0 | © 2013-2024
Impressum Informationssicherheit Datenschutz AGB
Letzte Änderung: 23.03.2023
x schließen